Aeglea BioTherapeutics announces name change to Spyre Therapeutics

Aeglea BioTherapeutics announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol “SYRE”. The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the company in June of 2023. Named to reflect the company’s ambition to achieve new heights in efficacy and convenience of Inflammatory Bowel Disease therapies, Spyre aims to create a next-generation of IBD products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision patient selection approaches to enhance efficacy for patients.